Aktis Oncology Q1 net loss widens on increased IPO-related expenses

Aktis Oncology

11/05/2026 21:13

Overview

US radiopharmaceutical developer's Q1 collaboration revenue more than doubled yr/yr

Net loss widened on higher R&D and administrative expenses as clinical pipeline advanced

Company completed $365 mln IPO in January, boosting cash to $538 mln at quarter end

Outlook

Company expects preliminary data from AKY-1189 Phase 1b trial in Q1 2027

Company plans to initiate AKY-2519 Phase 1b basket trial in H2 2026

Company expects in-house GMP facility to be operational in H2 2026

Result Drivers

R&D SPENDING - Higher research and development costs driven by Phase 1b clinical trial expenses for AKY-1189 and advancing AKY-2519 through IND-enabling studies, as well as increased hiring to support clinical pipeline

COLLABORATION REVENUE - Revenue growth attributed to continued advancement of research collaboration with Eli Lilly, recognized over time using the cost incurred input method

ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher employee-related costs and increased expenses associated with operating as a public company

Company press release: ID:nGNX5W4xrX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$3.23 mln
Q1 Net Income
-$18.33 mln
Q1 Operating Expenses
$25.93 mln
Q1 Operating Income
-$22.71 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Aktis Oncology Inc is $33.00, about 77.4% above its May 8 closing price of $18.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)